Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. develops therapies for gout and progressive kidney disease, with programs that include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy. The company also holds the VB4-P5 kidney anti-fibrotic program, a pre-IND asset targeting rare and prevalent forms of kidney disease.
Company announcements cover clinical and preclinical pipeline development, acquired kidney-disease assets, share consolidations, Nasdaq and TSX Venture Exchange listing matters, annual meeting results, board elections, auditor appointments, stock option plan approvals, and other governance actions tied to its public-company status.
XORTX Therapeutics (NASDAQ:XRTX) issued a corporate update on June 15, 2026 and appointed Mika Grasso as co-CEO, responsible for finance and public markets. The company is preparing an IND for its lead gout program XRx-026/XORLO, planning a two-part XRX-OXY-102 bridging study to support a 505(b)(2) NDA targeting gout patients intolerant to allopurinol, a US $700 million market. XORTX also outlines plans to pursue NDA submission, including potential accelerated approval, for XRx-008 in ADPKD and aims to advance its gout program toward marketing approval over the next 18 months.
XORTX (NASDAQ:XRTX) elected to voluntarily delist its common shares from the TSX Venture Exchange following a strategic review of dual-listing costs and regulatory requirements. The company expects benefits including lower exchange, legal and accounting fees, streamlined financing and greater management focus on advancing its XRx-026 gout program.
Shares will continue trading on Nasdaq, no shareholder action is required, and XORTX remains a reporting issuer in Alberta, British Columbia and Ontario.
XORTX (NASDAQ:XRTX) closed a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88, raising US$5 million in gross proceeds. The financing, still subject to final TSX Venture Exchange approval, will fund working capital, general corporate purposes, and investor relations activities.
E.F. Hutton & Co. acted as exclusive placement agent, earning a 4% (US$200,000) cash commission. According to the company, US$2.5 million of proceeds will be paid to IR Agency LLC for marketing and advertising services.
XORTX Therapeutics (NASDAQ:XRTX) priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share for expected gross proceeds of US$5 million before fees and expenses.
The pre-funded warrants are immediately exercisable at US$0.0001 and the offering is expected to close on or about May 15, 2026, subject to customary conditions and regulatory approvals.
XORTX (NASDAQ: XRTX) received a Nasdaq letter of compliance on April 20, 2026, curing a prior deficiency under Nasdaq Rule 5550(a)(2) that requires a US$1.00 minimum bid price.
Following a 1-for-5 reverse share split implemented April 6, 2026, the company’s shares traded at or above US$1.00 for 10 consecutive trading days, meeting the requirement on April 17, 2026.
XORTX (NASDAQ: XRTX) announced it closed the acquisition of the Vectus kidney anti-fibrotic asset, VB4-P5, on April 13, 2026 for an aggregate purchase price of US$3.0 million.
The Program includes a pre-IND small-molecule NCE, associated patent family, regulatory documentation and manufacturing data. Consideration: 154,544 common shares at US$3.5432 and 692,150 pre-funded warrants at US$3.5431 (exercise US$0.0001), warrants expire April 13, 2031 and include a 9.99% ownership cap. TSXV has conditionally approved listing of shares; common shares issued without a hold period under applicable Alberta rule.
XORTX (NASDAQ: XRTX) confirmed a 1-for-5 share consolidation will take effect on April 6, 2026. According to the company, the consolidation received required approvals from the TSX Venture Exchange and Nasdaq.
The move replaces every five old common shares with one new common share and will adjust the company’s issued and outstanding share count on the effective date.
XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026. Approximately 2,407,148 common shares were represented, about 35% of outstanding shares. All matters presented were approved, including election of five directors, auditor appointment, reapproval of the stock option plan, and approval of a share consolidation.
Detailed voting results are available in the Report of Voting Results filed on the company’s SEDAR+ profile.
XORTX (NASDAQ: XRTX) announced a change to the effective date of its previously disclosed share consolidation from March 27, 2026 to April 6, 2026. The consolidation remains a 1-for-5 share consolidation and is still subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company attributed the change to timing considerations and confirmed the consolidation will only proceed after receipt of all required exchange approvals.
XORTX (NASDAQ: XRTX) approved a one-for-five share consolidation effective March 27, 2026, reducing issued and outstanding common shares from 6,962,218 to approximately 1,392,444, subject to rounding. The action is intended to satisfy Nasdaq’s $1.00 continual listing requirement and a 10-day price condition by April 13, 2026.
No name change will occur. Fractional post-consolidation shares will be cancelled if under one-half or rounded up if one-half or greater; no cash will be paid for fractions. Convertible securities will be proportionately adjusted. Trading will resume under XRTX with new CUSIP 98420Q405.